KRAS G12C in advanced NSCLC (~13% of adenocarcinoma): sotorasib (CodeBreaK 100/200) and a...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-KRAS-G12C-NSCLC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-NSCLC |
| Sources | SRC-CIVIC SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Actionability Facts
| Biomarker | BIO-KRAS-G12C |
|---|---|
| Variant | G12C |
| Disease | DIS-NSCLC |
| ESCAT tier | IA |
| Recommended combinations | sotorasib monotherapy, adagrasib monotherapy |
| Contraindicated monotherapy | non-G12C KRAS — sotorasib/adagrasib not active on G12D/G12V/G13D/Q61 |
| Evidence summary | KRAS G12C in advanced NSCLC (~13% of adenocarcinoma): sotorasib (CodeBreaK 100/200) and adagrasib (KRYSTAL-1) are FDA/EMA-approved for previously-treated metastatic disease. ORR ~40%, PFS ~6 mo. Frontline KRYSTAL-7 (adagrasib + pembrolizumab) and CodeBreaK 202 ongoing. |
Notes
ESCAT IA. OncoKB Level 1. Reflex testing for KRAS G12C in metastatic NSCLC. STK11/KEAP1 co-mutations may modulate response.
Used By
No reverse references found in the YAML corpus.